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Abstract: Background/Aims: The current diagnostic workup of Cushing’s syndrome (CS) requires vari-
ous tests which only capture short-term cortisol exposure, whereas patients with endogenous CS generally
have elevated long-term cortisol levels. Scalp hair assessment has emerged as a convenient test in captur-
ing glucocorticoid concentrations over long periods of time. The aim of this multicenter, multinational,
prospective, case-control study was to evaluate the diagnostic efficacy of scalp hair glucocorticoids in
screening of endogenous CS. Methods: We assessed the diagnostic performances of hair cortisol (HairF),
hair cortisone (HairE), and sum of both (sumHairF+E), as measured by state-of-the-art LC-MS/MS tech-
nique, in untreated patients with confirmed endogenous CS (n=89), and community controls (n=295)
from the population-based Lifelines cohort study. Results: Both glucocorticoids were significantly ele-
vated in CS patients when compared to controls. High diagnostic efficacy was found for HairF (area under
the curve (AUC), 0.87 [95% CI, 0.83 to 0.92]), HairE (0.93 [0.89 to 0.96]) and sumHairF+E (0.92 [0.88
to 0.96]; all P<.001). Participants were accurately classified at optimal cut-off threshold in 86% of cases
(81% sensitivity, 88% specificity, 94% negative predictive value (NPV)) for HairF, in 90% of cases (87%
sensitivity, 90% specificity, 96% NPV) for HairE, and 87% of cases (86% sensitivity, 88% specificity, 95%
NPV) for the sum. HairE was shown to be most accurate in differentiating CS patients from controls.
Conclusion: Scalp hair glucocorticoids, especially hair cortisone, can be seen as a promising biomarker
in screening of CS. Its convenience in collection and workup additionally makes this feasible for first-line
screening
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Background/Aims: The current diagnostic workup of Cushing’s syndrome (CS) requires various tests 26	
which only capture short-term cortisol exposure, whereas patients with endogenous CS generally have 27	
elevated long-term cortisol levels. Scalp hair assessment has emerged as a convenient test in capturing 28	
glucocorticoid concentrations over long periods of time. The aim of this multicenter, multinational, 29	
prospective, case-control study was to evaluate the diagnostic efficacy of scalp hair glucocorticoids in 30	
screening of endogenous CS.  31	
Methods: We assessed the diagnostic performances of hair cortisol (HairF), hair cortisone (HairE), and 32	
sum of both (sumHairF+E), as measured by state-of-the-art LC-MS/MS technique, in untreated patients 33	
with confirmed endogenous CS (n=89), and community controls (n=295) from the population-based 34	
Lifelines cohort study.  35	
Results: Both glucocorticoids were significantly elevated in CS patients when compared to controls. 36	
High diagnostic efficacy was found for HairF (area under the curve (AUC), 0.87 [95% CI, 0.83 to 0.92]), 37	
HairE (0.93 [0.89 to 0.96]) and sumHairF+E (0.92 [0.88 to 0.96]; all P<.001). Participants were 38	
accurately classified at optimal cut-off threshold in 86% of cases (81% sensitivity, 88% specificity, 94% 39	
negative predictive value (NPV)) for HairF, in 90% of cases (87% sensitivity, 90% specificity, 96% NPV) 40	
for HairE, and 87% of cases (86% sensitivity, 88% specificity, 95% NPV) for the sum. HairE was shown 41	
to be most accurate in differentiating CS patients from controls.  42	
Conclusion: Scalp hair glucocorticoids, especially hair cortisone, can be seen as a promising biomarker 43	
in screening of CS. Its convenience in collection and workup additionally makes this feasible for first-line 44	























   
   
   
   
   
   
   































Cushing’s syndrome (CS) results from excessive exposure to glucocorticoid hormones and is associated 47	
with significant morbidity and mortality [1]. After exclusion of exogenous CS caused by glucocorticoid-48	
containing drugs, a variety of endogenous diseases can give rise to increased secretion of cortisol. 49	
Approximately 70% of the cases of endogenous CS is caused by a pituitary adenoma producing excessive 50	
ACTH, stimulating the adrenal to produce cortisol (i.e. Cushing’s disease). The remainder of endogenous 51	
CS cases mostly consists of adrenal causes and ectopic ACTH production [1]. 52	
 Endogenous CS is rare but often presents with common and therefore non-specific signs and 53	
symptoms such as weight gain, fatigue, metabolic syndrome features, and depression [2]. Features more 54	
specific for CS include easy bruising, facial plethora and proximal myopathy, but these do not occur in all 55	
patients [3]. This clinical dilemma can cause a significant delay in diagnosis, which is often made when 56	
the condition exists for an extended period of time and patients accumulate multiple signs and symptoms 57	
of CS. Current guidelines recommend three different first-line screening tests: 24-hour urinary free 58	
cortisol (UFC), late-night salivary cortisol (LNSC), and the 1 mg dexamethasone suppression test (DST) 59	
[4]. All three tests rely on patient compliance for the collection of the samples or drug intake, and their 60	
limitations often necessitate repeated testing. Furthermore, they may be influenced by several factors such 61	
as kidney function (for UFC), gingival microtrauma (for LNSC), and drug use (for the DST). 62	
 Recently, we reported the largest study thus far using measurements of scalp hair cortisol in 63	
patients with CS [5]. Scalp hair offers information about integrated cortisol exposure over months of time 64	
[6]. This may be particularly valuable in CS, where cortisol production may often vary across days. In our 65	
study, hair cortisol provided a 93% sensitivity and 91% specificity for CS, comparing well to first-line 66	
tests [5]. Furthermore, hair analysis can be used to create retrospective timelines of cortisol exposure, 67	























   
   
   
   
   
   
   






























 All studies measuring hair cortisol in CS thus far relied on immunoassays to quantify cortisol. A 69	
recent advance in the development of hair steroid analysis is hair steroid profiling using liquid 70	
chromatography-tandem mass spectrometry (LC-MS/MS). Recently, we have validated a method which 71	
measures hair values of cortisol, cortisone, testosterone, androstenedione, dehydroepiandrosterone sulfate 72	
(DHEAS), and 17-α-hydroxyprogesterone (17OHP) [9]. In contrast to immunoassays, LC-MS/MS is less 73	
prone to interference, offers higher sensitivity and can be used to measure multiple steroids 74	
simultaneously. The aim of this study was to assess the diagnostic efficacy of hair cortisol (HairF) and 75	
cortisone (HairE) measured by LC-MS/MS in two independently collected cohorts of patients with 76	























   
   
   
   
   
   
   






























Subjects and Methods 78	
Study participants 79	
Our study population consisted of 295 controls from the general Dutch population, which were also 80	
included in our previous study [10], and 89 patients with proven endogenous CS. All controls were 81	
recruited from Lifelines which is a multi-disciplinary prospective population-based cohort study 82	
examining in a unique three-generation design the health and health-related behaviors of 167,729 persons 83	
living in the North of The Netherlands. It employs a broad range of investigative procedures in assessing 84	
the biomedical, socio-demographic, behavioral, physical and psychological factors which contribute to 85	
the health and disease of the general population, with a special focus on multi-morbidity and complex 86	
genetics [11]. Patients were recruited from two clinic sites from the Netherlands (Erasmus MC, 87	
Rotterdam; n=19) and from Germany (Klinikum der Ludwig-Maximillians-Universität München, Munich; 88	
n=70). Diagnostic workup was performed as according to the guideline [4] and the diagnosis of CS, de 89	
novo or recurrence, was biochemically established by experienced endocrinologists and proven by 90	
surgery and/or additional investigations (e.g. bilateral inferior petrosal sinus sampling).  91	
Scalp hair measurements  92	
In all participants, a scalp hair sample of approximately 100-150 hairs was collected from the posterior 93	
vertex. Hair was cut as close to the scalp as possible and after sample collection stored in an envelope in 94	
the dark at room temperature. The protocol for hair processing and analysis was adapted from previous 95	
method described in detail elsewhere [9]. In short, approximately 20 mg of the proximal 3 cm (or the 96	
entire length of the hair sample, if the hair was shorter than 3 cm) was weighed and cut into 1 cm long 97	
pieces. Hair was washed in 2 mL of LCMS grade isopropanol for 2 minutes and allowed to fully dry. 98	
Steroids were extracted overnight in 1.4 mL of LCMS grade methanol, and 100 µL of cortisol-d3 and 99	
cortisone-d8 as internal standards for 18 hours at 25 degrees Celsius while the samples were being gently 100	























   
   
   
   
   
   
   






























of the extract was transferred to a clean tube. We then added 750 µL of methanol to the hair samples, 102	
which were spun down again, after which another 900 µL of extract was transferred to the tubes with 103	
extract. Extracts were evaporated under a continuous nitrogen stream at 37 degrees Celsius, reconstituted 104	
in 1 mL of purified water and 20 µL of methanol, and purified using solid phase extraction. Cortisol and 105	
cortisone concentrations were subsequently quantified by LC-MS/MS using a Xevo TQ-S system (Wates, 106	
Milford, MA). HairF and HairE were successfully determined in 91% and 97% of the study participants. 107	
Data on both hair glucocorticoids were available in 89% of the study population. The inter-assay 108	
coefficient of variation for cortisol and cortisone were 14.8% and 15.3%, respectively. The intra-assay 109	
coefficient of variation for cortisol and cortisone were <11% and <8%, respectively. The lower limit of 110	
quantification (LLoQ) of cortisol and cortisone were <1.3 and <9.3 pg/mg. For research purpose, HairF 111	
and HairE measurements below LLoQ were included in analyses as quantitative measures as no 112	
recognized substitution method exists.  113	
Statistical analysis 114	
We used SPSS version 24 (IBM Corp., Armonk, NY), and RStudio version 1.0.136 (RStudio, Inc., 115	
Boston, MA) with pROC package [12] for statistical analyses. Hair glucocorticoid values were 116	
logarithmically transformed to achieve a normal distribution and reported as geometric means and 95% 117	
confidence intervals (CI). Baseline characteristics were analyzed using ANCOVA when continuous, and 118	
using Chi-squared tests when categorical. Association between HairF and HairE was assessed by 119	
Pearson’s correlation. Diagnostic efficacy of HairF, HairE, and the sum of HairF and HairE (sumHairF+E) 120	
for CS screening was assessed by using receiver operator characteristic (ROC) curves. Optimal cut-offs, 121	
defined as the curve points closest to the top-left corner, were initially determined for cohort 1 and 2 122	
separately. For the main analyses, both cohorts were combined and optimal cut-off values were 123	
determined for the complete population. DeLong’s test was used to compare ROC curves between both 124	
cohorts. Paired analyses were additionally performed to assess the discriminating ability of the different 125	























   
   
   
   
   
   
   






























correctly classified subjects) and other diagnostic performance parameters (i.e. sensitivity, specificity, 127	
positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (LR
+
), and 128	
negative likelihood ratio (LR
-
)). Given the intra-individual and inter-assay coefficients of variation, we 129	
additionally calculated diagnostic performance parameters at 15 and 30% higher and lower levels than the 130	
optimal cutoffs. Furthermore, we performed sensitivity analysis in order to account for potential effects of 131	
exogenous glucocorticoids on hair glucocorticoid concentrations [10]. We repeated the main ROC 132	
analyses with only nonusers in the control cohort. This resulted in exclusion of in total 38 controls who 133	
had used any type of exogenous glucocorticoids in the previous three months. Among these participants, 134	
hair analyses were successful in 36/38 for HairF and sumHairF+E, and in 37/38 for HairE. All outcomes 135	























   
   
   
   
   
   
   































Descriptive characteristics and hair glucocorticoid concentrations 138	
Subjects characteristics and concentrations of hair glucocorticoids are shown in Table 1 and Figure 1. 139	
Controls were on average younger (42.3 years) when compared to patients (50.2 years). The majority of 140	
participants were women in both control group (74.6%) as well as CS group (74.2%). Hair 141	
glucocorticoids stratified for sex are shown in online supplementary Table S1. Men had in general higher 142	
levels of all measures, however, significant sex-differences in the three indices were only present in 143	
controls. Both male and female CS patients had higher values when compared to controls of same sex (all 144	
P<.001). Overall, there was a strong linear association between HairF with HairE (r=0.821, P<.001). The 145	
geometric mean HairF was higher in CS patients of cohort 1 (17.3 pg/mg [95%CI, 9.5 to 31.3]) and 146	
cohort 2 (11.7 pg/mg [95% CI, 8.5 to 16.2]) in comparison to controls (2.7 pg/mg [95% CI, 2.5 to 2.9], 147	
both P<.001]. HairE was also significantly higher in patients (cohort 1, 37.9 pg/mg [95% CI, 21.7 to 66.3]; 148	
cohort 2, 40.9 pg/mg [95% CI, 30.8 to 54.4]) in comparison to controls (8.2 pg/mg [95% CI, 7.8 to 8.7], 149	
both P<.001). The geometric mean of the sum of both hair glucocorticoids was additionally higher in CS 150	
patients than in controls. There were no statistically significant differences in hair glucocorticoids 151	
between patients from the two patient cohorts.  152	
Diagnostic efficacy of hair glucocorticoids for screening of Cushing’s syndrome 153	
ROC curves with corresponding diagnostic performance parameters for HairF, HairE, and sumHairF+E 154	
are depicted in Figure 2. Stratified analyses for sex are shown in online supplementary Figure S1. All 155	
three indices showed a strong significant differentiating efficacy in CS patients from both cohorts separate 156	
and combined (P<.001 for all area under curves (AUCs)). 157	
 For HairF, an optimal cut-off of 4.7 pg/mg (AUC, 0.87 [95% CI, 0.83 to 0.92]) was seen, with an 158	
accuracy of 86%, sensitivity of 81%, and specificity of 88%. A positive test result confirmed CS with 68% 159	























   
   
   
   
   
   
   






























pg/mg [AUC, 0.93 [0.89 to 0.96]). This formed the correct identification of 74/85 CS patients and 161	
261/289 controls corresponding to 90% accuracy, 87% sensitivity, and 90% specificity. The PPV and 162	
NPV with HairE were 73% and 96% respectively. The sum of both hair glucocorticoids also showed a 163	
high diagnostic efficacy with an AUC of 0.92 [95% CI, 0.88 to 0.96]). The optimal sumHairF+E cut-off 164	
was 18.9 pg/mg with a corresponding sensitivity of 86% and specificity of 88%. At this cut-off, 69/80 CS 165	
patients and 230/262 controls were identified correctly yielding an accuracy of 87% with 68% PPV and 166	
95% NPV.  167	
 In the context of sensitivity analyses to take potential influencing effects of glucocorticoid 168	
containing drugs into account, we found nearly identical AUCs when only nonusers were considered as 169	
controls (P<.001 for all three indices; data not shown). Moreover, optimal cut-off levels with 170	
corresponding sensitivity and specificity were also roughly similar for HairF (4.7 pg/mg, 81% sensitivity, 171	
87% specificity), HairE (13.8 pg/mg, 87% sensitivity, 89% specificity), and the sum (16.2 pg/mg, 89% 172	
sensitivity, 85% specificity). Diagnostic accuracy at these levels were 86% for HairF, 89% for HairE, and 173	
86% for sumHairF+E.  174	
 The optimal cut-off for all outcomes was lower in cohort 2 in comparison to cohort 1, however, 175	
only the sum of hair glucocorticoids was statistically significant different in the diagnostic efficacy 176	
between both cohorts (Figure 3). Paired ROC analysis of the hair glucocorticoids showed that HairE and 177	
sumHairF+E were more accurate in comparison to HairF in the screening of CS in the complete study 178	
























   
   
   
   
   
   
   































In this multicenter study, we evaluated, for the first time, the diagnostic efficacy of scalp hair cortisol and 182	
cortisone concentrations as measured by LC-MS/MS for the screening of CS in two independent patient 183	
cohorts. We show that both glucocorticoids are significantly elevated in patients when compared to 184	
community controls while there were no differences between the patient cohorts. With respect to 185	
diagnostic performances, we found high differentiating capacity of HairF (accuracy 86%, sensitivity 81%, 186	
specificity 88%), HairE (accuracy 90%, sensitivity 87%, specificity 90%), and the sum of both (accuracy 187	
87%, sensitivity 86%, specificity 88%). Excluding users of exogenous glucocorticoids in the control 188	
cohort revealed no significant effects on these findings. Paired analyses showed that HairE was more 189	
accurate than HairF or the sum in distinguishing patients from controls.  190	
Assessment of cortisol concentrations in scalp hair has previously been performed by us and 191	
others to compare levels between CS patients and controls [5, 7, 8, 13, 14]. Published studies consistently 192	
showed clearly elevated levels in patients in the proximal one and three cm hair segments. We have 193	
recently also investigated the diagnostic efficacy of HairF in distinguishing CS patients from healthy 194	
controls as well as patients suspected of CS but in whom the diagnosis was eventually excluded. High 195	
sensitivity and specificity were observed with similar optimal cut-offs for both analyses [5]. However, 196	
this and previous studies have only analyzed HairF and have performed analyses with immunoassay 197	
which is among others prone to cross-reactivity and is inferior to LC-MS/MS with respect to selectivity 198	
and detection. Findings of local production of 11β-hydroxysteroid dehydrogenase (11βHSD) type 1 and 2, 199	
which are respectively responsible for the conversion of cortisone into cortisol and vice versa, in skin, 200	
hair follicles and other cutaneous appendages [15-17] also complicates the interpretation of prior findings 201	
in CS patients. It therefore remains questionable whether the measured hair cortisol concentrations only 202	
reflect the actual past exposure to cortisol or whether these are altered due to local conversion by 203	
11βHSDs. Here we showed for the first time that HairF as well as HairE are elevated in CS patients and 204	























   
   
   
   
   
   
   






























diagnostic performance of HairE in distinguishing patients from controls when compared to HairF. 206	
Another test that might also be prone to local conversion effects is the first-line screening test with 207	
salivary cortisol, this because of the 11βHSD2 activity in parotid tissue [17]. A previous study by 208	
Perogamvros and colleagues focused on both salivary glucocorticoids in non-Cushingoid patients and 209	
found, similarly to the current work, higher concentrations of cortisone than cortisol whereas the opposite 210	
was true for the free fractions in serum. Interestingly, sampling after adrenal stimulation with ACTH 211	
injection showed salivary cortisone to reflect free serum cortisol more accurately than salivary cortisol 212	
[18]. Evaluation of salivary cortisol and cortisone in another study with CS patients indeed revealed high 213	
diagnostic accuracy for both measures [19]. Additionally, a recent study by Kapoor et al. with 214	
radiolabeled cortisol experiments in primates confirmed that circulating cortisol is taken up in hair and 215	
can be measured. Importantly, they also showed that a substantial proportion of the administered cortisol 216	
was incorporated as cortisone [20]. More research is however needed to understand the dynamics between 217	
cortisol and cortisone at local level and investigate the additional value of cortisone measurements.  218	
 The diagnostic efficacy of screening tests depends on the chosen cut-off value to differentiate 219	
patients from subjects without the disease. This makes it challenging to place our results in the context of 220	
the recommended tests. Nevertheless, Elamin et al. have systematically summarized and pooled the 221	
results of the traditional tests in the diagnostic workup of CS [21]. Based on this, the diagnostic efficacy 222	
of hair glucocorticoids, especially of HairE, seems to be quite similar to those of midnight salivary 223	
cortisol (pooled LR
+
 8.8 and LR
-
 0.1) and UFC (pooled LR
+
 10.6 and LR
-
 0.2), even though most 224	
included studies have a small population with a fairly high prevalence of CS [21]. Since the diagnosis of 225	
CS could not be relied on a single screening test, further research should especially address the diagnostic 226	
effectiveness of hair glucocorticoids in combination with other recommended tests. Besides, as mentioned 227	
in the guideline and also observed here, there is a substantial proportion of false-positives with the 228	
screening tests due to among others high prevalence of (mild) hypercortisolistic Cushingoid-like 229	























   
   
   
   
   
   
   






























Therefore the recommendation to restrict testing to subjects with a high a priori probability of having CS 231	
could reasonably be extended to hair glucocorticoids assessment.  232	
 The current screening tests are subjected to several difficulties and limitations which are less or 233	
completely absent with scalp hair measurements. From the patient’s perspective, the hair sampling is 234	
noninvasive, does not require to follow certain instructions (e.g. collection of urine output for at least 24 235	
consecutive hours for UFC) or impose restrictions (e.g. fasting or no teeth brushing before saliva 236	
collection for LNSC) as with the recommended tests, and it can be collected, stored, and posted by mail 237	
with ease which is especially useful for patients who have to cover long distances to clinic site. For the 238	
care professionals, it is convenient that hair measurements are not dependent on the time of day or patient 239	
compliance, and are not influenced by acute stressors. The unique feature of these measurements in 240	
covering long-term glucocorticoids exposure makes them additionally useful in the screening for cyclical 241	
CS. The current guideline recommends UFC or salivary cortisol measurements in case of suspicion of 242	
cyclical CS [4], however, these tests can yield normal results when patients are screened after the 243	
periodical increase in cortisol levels. We previously demonstrated the usefulness of hair measurements in 244	
such situations in multiple patients who had normal screening test results at the time of evaluation, but 245	
had retrospectively elevated cortisol concentrations in hair segments corresponding to the period of 246	
Cushingoid signs and symptoms [7]. 247	
 The large number of patients and controls as well as the multicenter evaluation are among the 248	
major strengths of the current work. Moreover, all hair glucocorticoid concentrations were determined 249	
with high sensitivity and specificity using state-of-the-art LC-MS/MS technique. This study is however 250	
limited in the way that controls from the community were not screened for CS. Nevertheless, given the 251	
rarity of this disorder with less than five cases per million individuals [22] it becomes very unlikely that 252	
controls were misclassified. Moreover, the results were not adjusted for potential confounders such as UV 253	























   
   
   
   
   
   
   






























would have substantially influenced the outcomes because of the large (5-6 fold) differences between 255	
controls and CS patients in hair glucocorticoids levels.  256	
 In conclusion, scalp hair assessment for hair glucocorticoids, in particular for cortisone 257	
concentrations, show a high diagnostic efficacy in differentiation CS patients from controls. Because of 258	
its simplicity and noninvasive sampling in addition to its diagnostic performances, this can be seen as a 259	
promising biomarker and a potential addition to the armamentarium of CS screening tests. In order to 260	
enable uniformly use of fixed cut-off values, we recommend further efforts to standardize or harmonize 261	
results between international centers.   262	
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Figure 1. Distribution of hair glucocorticoid concentrations in controls and Cushing’s syndrome 336	
patients. Hair cortisol (HairF), hair cortisone (HairE), and the sum of both are shown for community 337	
controls, and Cushing’s syndrome patients from two independent cohorts. Data for each group are 338	
summarized as geometric mean with corresponding 95% confidence interval. The solid black lines 339	
correspond to the optimal cut-off value and the dashed lines above and below indicate levels 340	
corresponding to 15% and 30% plus and minus the optimal cut-off value respectively.  341	
Figure 2. ROC analyses for diagnostic performance of hair glucocorticoids for Cushing’s syndrome. 342	
The red dots refer to the optimal cut-off (OC) value for screening of Cushing’s syndrome. The table 343	
summarizes the different diagnostic performance parameters at OC level and other specified levels. 344	
Abbreviations: AUC, area under the curve; HairE, hair cortisone concentrations; HairF, hair cortisol 345	
concentrations; OC, optimal cut-off threshold; LR, likelihood ratio; NPV, negative predictive value; PPV, 346	
positive predictive value; Sens, sensitivity; Spec, specificity.  347	
Figure 3. Comparisons of ROC curves for screening of Cushing’s syndrome by hair glucocorticoids 348	
between two independent patient cohorts.  349	
Figure 4. Paired analyses for differences in diagnostic efficacy between hair glucocorticoids for 350	
screening of Cushing’s syndrome.  Hair cortisone (HairE) was more accurate than hair cortisol (HairF), 351	
and the sum of both glucocorticoids (sumHairF+E) in differentiating patients with Cushing’s syndrome 352	
from controls. SumHairF+E was also statistically significant better than HairF with respect to diagnostic 353	
efficacy. 354	
Supplementary Figure S1. ROC analyses for diagnostic performance of hair glucocorticoids for 355	
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Table 1. Descriptive characteristics and hair glucocorticoids in controls and Cushing’s syndrome 1 




 Cushing’s syndrome patients 






Female (%) 220 (74.6%)  16 (84.2%) 50 (71.4%) 66 (74.2%) 
Age (years) 42.3 (±11.5)  44.2 (±16.7) 51.8 (±15.4) 50.2 (±15.9) 
Hair glucocorticoids (pg/mg) 
• Hair cortisol (HairF) 2.7  
(2.5 to 2.9) 
 17.3 
(9.5 to 31.3) 
11.7  
(8.5 to 16.2) 
12.7 
(9.6 to 16.9) 
• Hair cortisone (HairE) 8.2  
(7.8 to 8.7) 
 37.9 
(21.7 to 66.3) 
40.9  
(30.8 to 54.4) 
40.2 
(31.4 to 51.5) 
• Sum hair glucocorticoids 
(sumHairF+E) 
11.2  
(10.6 to 12.0) 
 63.7 
(39.4 to 102.9) 
49.7  
(38.1 to 65.0) 
52.6 
(41.8 to 66.2) 























   
   
   
   
   
   
   


















































































































































































































   
   
   
   
   
   
   



































  Cushing’s syndrom
 n Cohort 1 n Cohort 2 
Hair glucocorticoids (pg/mg) 
• Hair cortisol (HairF) Female 194 2.5 (2.3 to 2.8)  15 14.9 (7.7 to 29.0)  46 10.1 (6.9 to 15.
Male 72 3.2 (2.7 to 3.8)  3 36.0 (2.6 to 502.9) 19 16.6 (9.0 to 30.
         
• Hair cortisone (HairE) Female 216 7.8 (7.4 to 8.3)  16 34.8 (18.6 to 65.1) 48 40.2 (28.9 to 56.
Male 73 9.4 (8.3 to 10.7)  3 60.1 (3.4 to 1063.9) 18 42.6 (22.9 to 79.
         
• Sum hair glucocorticoids (sumHairF+E) Female 192 10.7 (10.0 to 11.5)  15 58.6 (34.6 to 99.3) 45 47.8 (34.4 to 66.
Male 70 12.7 (11.1 to 14.6)  3 96.2 (5.9 to 1559.6) 17 55.4 (33.6 to 91.























   
   
   
   
   
   
   
   
 
13
0.
60
.1
31
.6
6 
- 3
/1
8/
20
19
 1
2:
22
:4
3 
PM
Ac
ce
pte
d m
an
us
cri
pt
